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Is the NHS really “off the table” in post-Brexit talks
with the US?
No, the UK risks losing control over critical elements of NHS policy
Johanna Hanefeld associate professor of health policy and systems 1, Richard Smith professor of
health economics  2
1London School of Hygeine and Tropical Medicine, London, UK; 2College of Medicine and Health, University of Exeter, Exeter, UK
Since leaked minutes of US-UK trade talks were made public
on 25 November, a predictable war of words has been ongoing
between the political parties and the media. But what do these
revelations actually tell us about the possible impact of a
post-Brexit US trade deal on the NHS? We have examined six
sets of minutes1 and find two clear messages.
Firstly, these documents make clear the extent and form of US
interest in the NHS, and it seems unlikely that factors affecting
the provision of health services would be excluded from trade
agreement negotiations. The NHS as a whole may not
technically “be on the table,” but depending how negotiations
are concluded, there is real potential for an agreement that
greatly undermines the UK’s sovereignty over policy decisions
in this space and the government’s ability to determine spending
on health and the NHS.
Sovereignty undermined
Reading these documents creates a sense of déjà vu relating to
the recently aborted Trans Pacific Partnership (TPP) agreement,9
with the added irony that a trade agreement with the US could
put the UK in a position that seems to be the opposite of the
Brexit rhetoric of “taking back control.” In particular, proposals
that we should give US drug companies greater market access
and longer patent protection2-4 will result in higher drug prices
and are likely to weaken the UK’s evidence based policy
mechanisms, including the role of the National Institute for
Health and Clinical Excellence (NICE). Mechanisms such as
NICE, which determines the supply of medicines based on a
technical rather than political review of evidence of benefit and
cost, are an essential component of equitable, fair, and
accountable decision making in the NHS. This would effectively
decrease the UK’s sovereignty over healthcare.
The leaked papers are obviously chronicles of preliminary
discussions. However, they leave little doubt about the extent
to which intellectual property, especially in relation to
medicines, is a central focus for the US in any free trade
agreement with the UK. This position is consistent with a long
history of trade negotiations in which the US has sought to
ensure market access and patent protection for the benefit of
US corporations, with central considerations given to the US
drug industry: five of the world’s 10 largest drug companies
have headquarters in the US.10
Focus on medicines
Secondly, the leaked documents show the US trade negotiators’
clear focus on medicines and patents for medicines. There are
repeated references to pharmaceuticals, patents, the length of
patent protection, market access, and registration processes. The
consistency with which patent protection, in particular, is
referred to leaves little doubt that this is a priority for the US.
Reference to the UK’s helpful talks with the Pharmaceutical
Research and Manufacturers of America, which lobbies for the
US drug industry, underlines this point.
The extent to which the US focuses on the UK’s patent systems
and European regulation also suggests that weakening the UK’s
patent system so that is more closely aligned with that of the
US is seen as strategic, with potential implications for patent
rules beyond the UK. Concerns have also been raised about the
potential for US companies to mine and monetise NHS patient
data.5
The proposals show a remarkable similarity to US negotiations
with many low and middle income countries over the commonly
termed “TRIPS-plus” protections.6 Literature relating to these
experiences indicates the pressure placed on countries to offer
patent and other measures that far exceed those required under
the internationally agreed TRIPS system. It is sobering to reflect
on this when considering how the UK’s NHS, as a weaker
partner, may fare in trade negotiations with the US.7
Finally, governance mechanisms that allow companies to
challenge public health regulations through trade disputes also
raise the possibility of a “tit for tat” trade war around public
health matters, adding considerable pressure to these
deliberations.8 For example, the US may threaten to impose
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restrictions on UK goods if it is argued that public health
regulations are preventing free trade.
US success in securing longer patents would undoubtedly force
the NHS to pay higher prices for medicines for longer. Beyond
these headlines, however, we must not ignore the wider
implications of a free trade agreement—loss of sovereignty and
decision making power for the UK, including decision making
on the NHS.
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